Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,016 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.
Deguchi T, Shikano T, Kasuya H, Nawa A, Fujiwara S, Takeda S, Gewen T, Sahin TT, Yamada S, Kanzaki A, Yamamura K, Fujii T, Sugimoto H, Nomoto S, Fukuda S, Nishikawa Y, Kodera Y, Nakao A. Deguchi T, et al. Among authors: fukuda s. Hepatogastroenterology. 2012 Sep;59(118):1844-50. doi: 10.5754/hge11566. Hepatogastroenterology. 2012. PMID: 22172413
Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer.
Shirota T, Kasuya H, Kodera Y, Nishikawa Y, Shikano T, Sahin TT, Gewen T, Yamamura K, Fukuda S, Kanzaki A, Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Nakao A. Shirota T, et al. Among authors: fukuda s. Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1482-9. doi: 10.5754/hge11168. Epub 2011 Jul 15. Hepatogastroenterology. 2011. PMID: 21940320
Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10.
Yamamura K, Kasuya H, Sahin TT, Tan G, Hotta Y, Tsurumaru N, Fukuda S, Kanda M, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Fujii T, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Tanaka M, Kodera Y. Yamamura K, et al. Among authors: fukuda s. Ann Surg Oncol. 2014 Feb;21(2):691-8. doi: 10.1245/s10434-013-3329-3. Epub 2013 Oct 30. Ann Surg Oncol. 2014. PMID: 24170435
Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
Tan G, Kasuya H, Sahin TT, Yamamura K, Wu Z, Koide Y, Hotta Y, Shikano T, Yamada S, Kanzaki A, Fujii T, Sugimoto H, Nomoto S, Nishikawa Y, Tanaka M, Tsurumaru N, Kuwahara T, Fukuda S, Ichinose T, Kikumori T, Takeda S, Nakao A, Kodera Y. Tan G, et al. Among authors: fukuda s. Int J Cancer. 2015 Apr 1;136(7):1718-30. doi: 10.1002/ijc.29163. Epub 2014 Sep 27. Int J Cancer. 2015. PMID: 25156870
Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.
Kasuya H, Kodera Y, Nakao A, Yamamura K, Gewen T, Zhiwen W, Hotta Y, Yamada S, Fujii T, Fukuda S, Tsurumaru N, Kuwahara T, Kikumori T, Koide Y, Fujimoto Y, Nakashima T, Hirooka Y, Shiku H, Tanaka M, Takesako K, Kondo T, Aleksic B, Kawashima H, Goto H, Nishiyama Y. Kasuya H, et al. Among authors: fukuda s. Hepatogastroenterology. 2014 May;61(131):599-605. Hepatogastroenterology. 2014. PMID: 26176043 Clinical Trial.
Prognostic Analysis of Pathological Stage I Lung Adenocarcinoma Harboring Major EGFR Mutations.
Takamori S, Endo M, Hamada A, Ohara S, Fukuda S, Tomioka Y, Takamori S, Osoegawa A, Nomura K, Fujino K, Yoshikawa M, Suzawa K, Shien K, Suda K, Kinoshita F, Hayasaka K, Notsuda H, Nagano T, Matsudo K, Hashinokuchi A, Matsubara T, Katsumata S, Shiono S, Soh J, Ohde Y, Shimokawa M. Takamori S, et al. Among authors: fukuda s. Clin Lung Cancer. 2024 Dec 26:S1525-7304(24)00284-5. doi: 10.1016/j.cllc.2024.12.011. Online ahead of print. Clin Lung Cancer. 2024. PMID: 39824660
3,016 results